FDA approval is only the first hurdle for new cancer therapies. Inclusion in NCCN guidelines as a preferred regimen is the critical next step. This update validates a treatment's practice-changing potential and, more pragmatically, serves as a key signal for insurance companies to provide reimbursement.
This new combination therapy for triple-negative breast cancer showed no increased toxicity compared to its individual components. Surprisingly, immune-related side effects were numerically lower than in the standard chemotherapy-immunotherapy arm, highlighting a favorable safety profile that is crucial for patient management.